Business
Exercise of Options
Exercise of Options.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 5066S Allergy Therapeutics PLC 24 September 2014 \n \n\n24 September 2014\n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or \"the Company\")\n \nExercise of Options\n \n \nAllergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 188,500 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence in these shares on 30 September 2014. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company. The total number of shares in issue (inclusive of the above issue) is 410,055,331 Ordinary shares of 0.1p each. \n \n \n \nFor further information\n\n\n\n\nAllergy Therapeutics\n\n\n+44 (0) 1903 845 820\n\n\n\n\nManuel Llobet, Chief Executive Officer\nIan Postlethwaite, Finance Director\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP \n\n\n+44 (0) 20 7418 8900 \n\n\n\n\nJames Steel\nClare Terlouw\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting\n\n\n+44 (0) 20 3727 1000\n\n\n\n\nSimon Conway \nVictoria Foster Mitchell\n\n\n\n\n\n\n\n \n \nNotes to editors\n \nAbout Allergy Therapeutics\nAllergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the current financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets. \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END RDSEAANLAFXLEFF\n ","length":4571,"tagName":"div"}]